BIOBio-Rad Laboratories, Inc.
Price
+29%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, no red flags, demanding price, growth fading, the market undecided.
Bio-Rad Laboratories, Inc. (referred to in this report as “Bio-Rad,” “we,” “us,” “the Company,” and “our”) is a multinational life science and clinical diagnostics company that develops, manufactures, and markets a broad portfolio of instruments, systems, reagents, and consumables. We have direct operations in over 36 countries outside the United States through subsidiaries focused on sales, customer service, and product distribution.
In the company’s own words · 10-K filed Feb 13, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Bio-Rad Laboratories, Inc. (BIO) reported revenue of $651M in Q2 2026 (quarter ended Jun 30, 2026), down 0.1% from the same quarter a year earlier. That came with a gross margin of 53% and net income of $371M (57% of revenue). For the full year FY2025, revenue was $2.58B (+0.7% year on year) and net income $760M. Its largest region in Q2 2026 was United States at $256M, 39% of the disclosed total, just ahead of Europe at 35%. The next results filing is expected around Oct 28, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 4, 2026On July 31, 2026, Bio-Rad Laboratories, Inc. (the “Company ") initiated a strategy-driven restructuring plan as part of our ongoing program to improve operating performance and strengthen the Company’s competitive position.Earnings release · Form 8-K
- Apr 30, 2026Bio-Rad Reports First -Quarter 2026 Financial Results.Earnings release · press release
- Apr 24, 2026On April 21, 2026, at the annual meeting of stockholders (the “Annual Meeting”) of Bio-Rad Laboratories, Inc. (the “Company”), as further described in.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $651.0MThe company’s own SEC segment disclosure.
- United States$255.5M39%
- Europe$229.2M35%
- Asia Pacific$121.8M19%
- Americas$44.5M7%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Devices
Ranks #22 of 51 by RyuScore